REGENHU announced today that it is participating in a FLAMIN-GO research project aimed at developing organ-on-chip technology for clinical trials of Rheumatoid Arthritis (UK).
FLAMIN-GO is an EU-funded project that brings together a strong, balanced mix of hospitals, academics and business partners that brings together the expertise of experts in the fields of rheumatology, materials science, print engineering, nanotechnology, cell biology. , and 3D modeling, in a coherent, cross-disciplinary, multidisciplinary approach. The goal is to develop the next generation of personal synovia-on-chip, which, by effectively mimicking the complexity of the UK joint, allows for on-chip personal clinical trials, and at the eventually opening new avenues towards personalized care in the UK.
“FLAMIN-GO has been meticulously designed with the intention of opening a new pathway to personal therapy in the treatment of Rheumatoid Arthritis. The goal is to provide an organ-on-chip (OoC) solution where the best drug on the market can be selected for the treatment of each patient, which will also support the development of new drugs. This solution will be based on the design and production of a multi-platform microfluidic platform for 3D cell culture and the breakdown of all disease-related components, ”said Annalisa Chiocchetti, project coordinator and Professor of Immunology at East Piedmont University in Novara.
REGENHU’s involvement in the consortium will be threefold: the company will provide (a) a custom 3D bioprinter and associated design software capable of printing cell lines into to the organ slits in a highly reproducible and accurate manner with high cell viability. (b) training in the use of bioprinter and software, and (c) technical support to members of the consortium in resolving issues with biomaterials printing.
“For REGENHU, joining FLAMIN-GO is a major step forward in maintaining our leadership in 3D bioprinting innovation,” said Simon Mackenzie, Chief Executive, REGENHU. “We believe that the knowledge gained in the consortium will lead to the discovery of new approaches that will help deliver meaningful, modern solutions to millions of patients. living with the UK across Europe. ”
About rheumatoid arthritis
Rheumatoid arthritis is an autoimmune inflammatory disorder, characterized by synovial joint inflammation, affecting 1% of the total population. This condition affects around 2.9 million patients in the EU.
Over time, RA can lead to permanent disability. Currently, there is no cure for RA, but symptom relief is more likely when treatment begins early, with disease-modifying antirheumatic drugs (DMARDs).
In FLAMIN-GO
FLAMIN-GO is a research project designed to develop “specific” treatments for all patients with rheumatoid arthritis. Led by the University of Eastern Piedmont, the project is the result of collaboration between a range of public and private bodies, including the National Research Council’s Institute of Nanotechnology (Cnr Nanotec) at Lecce, Queen’s University Mary London, the Max Planck Institute, and Swiss AO Research Institute Davos, ARI.
In REGENHU
REGENHU is a Swiss bioprinter pioneer MedTech committed to supporting the research and scientific communities by creating and developing state-of-the-art bioprinting technologies to transform medicine.
Founded in 2007, the fast-expanding dynamic company is based in Villaz-St-Pierre, Switzerland, with offices in the United States, and distributors in Asia and Oceania.